Mycobacterium abscessus cDNA and Antigen

Mycobacterium abscessus is a rapidly growing nontuberculous mycobacterium that can cause a variety of infections in humans, particularly in individuals with weakened immune systems. Several key antigens have been identified in association with Mycobacterium abscessus, and these antigens play important roles in the virulence and immune response to the bacterium.

18 kDa antigen HSP 16.7: The 18 kDa antigen HSP 16.7 is a heat shock protein that is produced by Mycobacterium abscessus. This antigen is involved in stress response, adaptation to adverse environmental conditions, and immune evasion. It has been identified as a key antigen and a potential target for diagnostics and therapeutic interventions for Mycobacterium abscessus infections.

Antigen 85-A-B-C: The antigen 85 complex is a group of closely related proteins, including Antigen 85-A, Antigen 85-B, and Antigen 85-C, that are produced by Mycobacterium abscessus. These proteins are involved in cell wall biosynthesis and have been implicated in the pathogenesis of Mycobacterium abscessus infections. They have been identified as key antigens and potential targets for diagnostics and therapeutics.

ESAT-6 (10 kDa antigen): ESAT-6 is a 10 kDa antigen that is produced by Mycobacterium abscessus. It is a protein that is secreted by the bacterium and is involved in host-pathogen interactions, including immune modulation and evasion. ESAT-6 has been identified as a key antigen and a potential target for diagnostics and therapeutics.

Antigen Mtb12: Antigen Mtb12 is a protein antigen that is produced by Mycobacterium abscessus. It is a secreted protein that has been shown to induce strong immune responses in infected individuals. Antigen Mtb12 has been identified as a key antigen and a potential target for diagnostics and therapeutics.

29 kDa antigen CFP29: The 29 kDa antigen CFP29 is a protein antigen that is produced by Mycobacterium abscessus. It is a cell wall-associated protein that has been implicated in the pathogenesis of Mycobacterium abscessus infections. CFP29 has been identified as a key antigen and a potential target for diagnostics and therapeutics.

36 kDa antigen: The 36 kDa antigen is a protein antigen that is produced by Mycobacterium abscessus. It is involved in cell wall biosynthesis and has been implicated in the pathogenesis of Mycobacterium abscessus infections. The 36 kDa antigen has been identified as a key antigen and a potential target for diagnostics and therapeutics.

Soluble secreted antigen MPT53: MPT53 is a soluble secreted protein antigen that is produced by Mycobacterium abscessus. It is involved in host-pathogen interactions and has been shown to induce immune responses in infected individuals. MPT53 has been identified as a key antigen and a potential target for diagnostics and therapeutics.

60 kDa chaperonin: The 60 kDa chaperonin is a protein antigen that is produced by Mycobacterium abscessus. It is involved in protein folding and has been implicated in the pathogenesis of Mycobacterium abscessus infections. The 60 kDa chaperonin has been identified as a key antigen and a potential target for diagnostics and therapeutics.

These antigens of Mycobacterium abscessus have the potential to be used in diagnostic tests, such as serological assays.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

Mycobacterium abscessus cDNA can be used to create recombinant antigens for the diagnosis and treatment of Mycobacterium abscessus infections. Recombinant antigens are produced by introducing the cDNA into an expression vector, such as an Escherichia coli plasmid, and then expressing the recombinant antigen in the host cell. The expressed recombinant antigens can then be purified and used as diagnostic or therapeutic agents. For example, recombinant antigens can be used to detect antibodies specific to M. abscessus in patient serum samples, which can aid in the diagnosis of M. abscessus infections. Additionally, recombinant antigens can be used as therapeutic vaccines to provide protection against M. abscessus infections.